New drug cocktail aims to stop childhood cancer relapse

NCT ID NCT04469530

First seen Mar 01, 2026 · Last updated May 20, 2026 · Updated 7 times

Summary

This study tests whether giving children with high-risk solid tumors a daily combination of sirolimus and low-dose chemotherapy for 12 months after standard treatment can keep the cancer from coming back. About 55 participants aged 1 to 30 years will take part. The goal is to see if this maintenance approach improves the chance of being cancer-free two years later compared to just watching and waiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aflac Cancer & Blood Disorders Centers

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Healthcare of Atlanta

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC)

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Texas Children's Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.